Amedisys (AMED) Tops Q4 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Amedisys (AMED) PT Lifted to $28 at Piper Jaffray; 'Hold' Maintained
March 5, 2015 7:20 AM ESTPiper Jaffray analyst Kevin Ellich bumped his price target on Amedisys (NASDAQ: AMED) to $28.00 (from $24.00) following in-line Q4 results but maintained a Neutral rating.
Ellich commented, "4Q14 results were in line with consensus driven by continued operational improvement. While AMED did not provide 2015 guidance,... More
